PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

James F. List, Vice President At BMS to Speak At Diabetes Summit on April 19-20 in Boston - James F. List, Vice President, Full Development Lead, Dapagliflozin, Metabolics, R&D, Bristol-Myers Squibb will participate in the panel discussion at the 2nd Diabetes Summit to - GTCbio.com
James F. List, Vice President At BMS to Speak At Diabetes Summit on April 19-20 in Boston

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/03/09 - James F. List, Vice President, Full Development Lead, Dapagliflozin, Metabolics, R&D, Bristol-Myers Squibb will participate in the panel discussion at the 2nd Diabetes Summit to - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

James F. List, Vice President, Metabolics, R&D, and Full Development Lead of Dapagliflozin, at Bristol-Myers Squibb will participate in the panel discussion called “Beyond HbA1c - Are there Better Endpoints for Clinical Trials?” at the 2nd Diabetes Summit to be held on April 19-20, 2012 in Boston, MA by GTC.

Other panelists in the panel discussion include Lane Desborough, Product Strategist at Medtronic, Claudia Graham, Ph.D., MPH, Vice President of Marketing & Global Access, Dexcom, and Solomon Steiner, Managing Partner at Steiner Ventures. The panel will discuss various topics such as why HbA1c may not be an ideal endpoint for clinical trials and what would it take to achieve a new standardized endpoint for clinical trials.

James F. List, M.D., Ph.D. is Vice President at Bristol-Myers Squibb. In 2011, Dr. List was appointed Full Development Lead for dapagliflozin, an SGLT-2 inhibitor being developed for the treatment of type 2 diabetes. He has responsibility to oversee the rigorous and efficient development and registration of the compound.

Dr. List joined Bristol-Myers Squibb in 2004 as Associate Director of Clinical Development and Evaluation in the area of metabolics, where he provided leadership for a number of global phase 2 and 3 studies, including pivotal studies in the development program of Onglyza.

Dr. List holds bachelors and masters degrees in Medical Microbiology and Philosophy of Science, respectively, from Stanford University. He received his M.D. and his Ph.D. in Microbiology and Immunology from the University of Minnesota. He received training in Internal Medicine at Brigham and Women’s Hospital, in Pediatrics from Children’s Hospital Boston, and in Endocrinology at Massachusetts General Hospital.

With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?

Come and join other diabetes experts at GTC’s 2nd Diabetes Summit and hear key thought-leader's opinions to these questions and many more. This important meeting will be held on April 19-20, 2012 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons learned from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.

The 2nd Diabetes Summit will consist of 2 tracks:

• 5th Diabetes Drug Discovery and Development.
• 2nd Diabetes Partnering & Deal Making.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


James F. List, Vice President At BMS to Speak At Diabetes Summit on April 19-20 in Boston

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)